Zai Lab has a broad and validated late-stage pipeline in oncology, infectious disease and autoimmune. We currently have 25 assets with 12 in late stage, 11 internally developed assets with global rights, 3 products commercialized in China and 5 products approved in the U.S. (marked with * below).
Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
Ovarian Cancer (1st line maintenance)*
China
Ovarian Cancer (2nd line maintenance) *
China
Gastric Cancer, Biliary Tract Cancer and Triple Negative Breast Cancer ( (I/O[3] combo)[1]
Other solid tumors[2] (I/O[3] combo)
Infectious Disease and Autoimmune
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
Note: [1] China-only trials; [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.